news
Mechanism that causes ALS nerve destruction unveiled for first time
The study reveals the biological mechanism that causes nerve destruction in amyotrophic lateral sclerosis (ALS), potentially leading to treatments that reverse the disease.
List view / Grid view
Neurons
news
New target for overeating identified in the brain’s cerebellum
The study uncovered disordered signalling in the brain's cerebellum, offering a novel therapeutic target for Prader Willi syndrome.
news
Altered fat metabolism shown to play a key role in ALS
Scientists reveal that higher levels of inflammatory chemicals involved in fat metabolism occur in people with amyotrophic lateral sclerosis.
news
Scientists reveal ultrastructure of Huntington’s disease
Researchers used advanced microscopy and proteomics to unveil new findings on Huntington's disease and open avenues to future treatments.
news
Intranasal drug may be the future of depression treatments
Groundbreaking study succeeded in the intranasal delivery of an anti-depressant peptide-based drug to the brain in mouse models.
news
Scientists explore CA2 neuron mitochondria for memory loss targets
The team will receive $2 million over five years to investigate the CA2 brain region for the development of neurological therapies.
news
Soluble fibrinogen a potential target for neurodegeneration
In a pre-clinical study, fibrinogen increased the death of mouse brain neurons, suggeting fibrin can have similar toxic effects on neurons.
news
Alterity’s ATH434 improves Parkinson’s-related gastrointestinal dysfunction
ATH434 reversed some of the gastrointestinal damage to the enteric nervous system associated with Parkinson's disease in a pre-clinical study.
news
Gene therapy bolsters Parkinson’s drug benefits in pre-clinical study
The gene therapy restored the ability of neurons to convert levodopa to dopamine and may help develop therapies to slow disease progression.
news
Scientists target ALS and dementia RNA using novel molecule
The small molecule successfully targeted the C9orf72 gene that causes amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
news
Gene therapy shows promise for Angelman syndrome treatment
A new gene therapy restored motor skill-learning and usual behaviours in Angelman syndrome mouse models, suggesting a novel therapy for the condition.
article
Peptides: a promising alternative to opioids for chronic pain relief
In an exclusive with Drug Target Review, researchers at the University at Buffalo explain how they developed a novel peptide that could be a future treatment for chronic inflammatory pain.
news
Scientists identify protein that prevents HSV-1 brain damage
Mammalian target of rapamycin complex 2 (mTORC2) was found to prevent brain damage in mice infected with herpes simplex virus 1 (HSV-1).
news
Mission Therapeutics receives $500k grant for Parkinson’s research
Mission Therapeutics was granted $500,000 from the The Michael J Fox Foundation for Parkinson’s Research for DUB inhibitor testing.
news
Stealth BioTherapeutics reports positive pre-clinical data for ALS candidate
Stealth BioTherapeutic's SBT-272 improved mitochondrial motility in a murine model of amyotrophic lateral sclerosis.